The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older

Prior treatment

• Previous or current treatment with chemotherapy
• Renal Transplant Clips
• Hearing Aids /implant
• Ocular Implants
• Hair implants

Other illness

• As per medical record or self-report, a history of central nervous system stroke, history of traumatic brain injury, or diagnosis of neurogenerative disorder that affects cognitive function (e.g. Alzheimer's, Parkinson's, Multiple Sclerosis, dementia, seizure disorders, etc.)
• History of untreated psychiatric disease
• As per medical record or self-report, history of loss of consciousness for 60+ minutes and/or admitted to the hospital for a head injury
• History of developmental disorders
• Current or history of alcohol or substance abuse
• Visual, auditory, or other impairment that would preclude ability to complete neuropsychological testing (e.g. significant macular degeneration, being unable to correct hearing with hearing aides, hand tremors, etc.)
  • CRITERIA FOR OPTIONAL fMRI
• Cardiac pacemaker
• Artificial heart valve

Other

• All Groups
• Current use of opioids
• Patient has a self-reported fear of enclosed spaces (Claustrophobia)
• As per self report or as identified in the medical record, patient has any of the following items that preclude fMRI evaluation:
• Joint replacements
• Aneurysm clips
• Transdermal patched
• Aortic clips
• Prosthesis
• Intracranial bypass clips
• Harrington rod
• Coronary Artery bypass clips
• Biostimulator
• Bone or joint pins
• Other vascular clips or filters
• Tissue expander
• Implanted neurostimulators
• Metal mesh
• Stents
• Insulin pump
• Wire structures
• Electrodes
• Shrapnel/bullets
• Implanted electrical devices
• IUD Metal in eyes
• Shunts
• Hair extensions
• Tattoos above the waist
• Any possible metal in body
• As per self report, patient has dentures, body jewelry or wig that they are unable to remove

• Comparison Androgen Ablation Group
• Diagnosis of prostate cancer
• Age 65 or older
• Ability to converse, write and read English
• In the investigator's judgment, participants must have satisfactory cognitive function to provide valid informed consent and participate in the neurocognitive testing. The Blessed Orientation-Memory-Concentration test (BOMC) will be used as a cognitive screening tool. Patients must have a BOMC score of less than or equal to 11.
• Able to provide informed consent
• Have been on continuous androgen ablation therapy for 6 months to-3 years
  • Longitudinal Androgen Ablation Subgroup
• Diagnosis of prostate cancer
• Age 65 or older
• Ability to converse, write and read English
• Able to provide informed consent
• In the investigator's judgment, participants must have satisfactory cognitive function to provide valid informed consent and participate in the neurocognitive testing. The Blessed Orientation-Memory-Concentration test (BOMC) will be used as a cognitive screening tool. Patients must have a BOMC score of less than or equal to 11.
• Starting androgen ablation therapy or started within the past 21 days
• No androgen ablation therapy within the past year
  • No Androgen Ablation Subgroup
• Diagnosis of prostate cancer
• Age 65 or older
• In the investigator's judgment, participants must have satisfactory cognitive function to provide valid informed consent and participate in the neurocognitive testing. The Blessed Orientation-Memory-Concentration test (BOMC) will be used as a cognitive screening tool. Patients must have a BOMC score of less than or equal to 11.
• At least 1-year post definitive localized treatment
• Ability to converse, write and read English
• Able to provide informed consent
• Not anticipated to start androgen ablation therapy
• No history of androgen ablation therapy